NO20032913D0 - Neurotrofiske tacrolimusanaloger - Google Patents

Neurotrofiske tacrolimusanaloger

Info

Publication number
NO20032913D0
NO20032913D0 NO20032913A NO20032913A NO20032913D0 NO 20032913 D0 NO20032913 D0 NO 20032913D0 NO 20032913 A NO20032913 A NO 20032913A NO 20032913 A NO20032913 A NO 20032913A NO 20032913 D0 NO20032913 D0 NO 20032913D0
Authority
NO
Norway
Prior art keywords
neurotrophic
tacrolimus
analogues
tacrolimus analogues
neurotrophic tacrolimus
Prior art date
Application number
NO20032913A
Other languages
English (en)
Norwegian (no)
Inventor
Nobuya Matsuoka
Takayuki Yamaji
Bruce Gold
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20032913D0 publication Critical patent/NO20032913D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20032913A 2000-12-29 2003-06-24 Neurotrofiske tacrolimusanaloger NO20032913D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29
PCT/US2001/050419 WO2002053159A1 (en) 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs

Publications (1)

Publication Number Publication Date
NO20032913D0 true NO20032913D0 (no) 2003-06-24

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032913A NO20032913D0 (no) 2000-12-29 2003-06-24 Neurotrofiske tacrolimusanaloger

Country Status (18)

Country Link
EP (1) EP1353671A4 (cs)
JP (1) JP2004527472A (cs)
KR (2) KR100794204B1 (cs)
CN (1) CN1293877C (cs)
AR (1) AR035411A1 (cs)
AU (1) AU2002231277B2 (cs)
BR (1) BR0116762A (cs)
CA (1) CA2433384A1 (cs)
CZ (1) CZ20032060A3 (cs)
HU (1) HUP0302521A3 (cs)
IL (1) IL156664A0 (cs)
MX (1) MXPA03005941A (cs)
NO (1) NO20032913D0 (cs)
NZ (1) NZ527209A (cs)
PL (1) PL366301A1 (cs)
RU (1) RU2288716C2 (cs)
WO (1) WO2002053159A1 (cs)
ZA (1) ZA200305806B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
CA2554045A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
JP2009102226A (ja) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd 脊髄損傷治療剤
RU2521286C2 (ru) * 2008-07-23 2014-06-27 Новартис Аг Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани
WO2013124416A1 (en) * 2012-02-23 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US537663A (en) * 1895-04-16 wubstee
EP0346427B1 (en) * 1987-12-09 1995-03-29 FISONS plc Macrocyclic compounds
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use

Also Published As

Publication number Publication date
CN1538843A (zh) 2004-10-20
MXPA03005941A (es) 2005-02-14
CN1293877C (zh) 2007-01-10
RU2003123493A (ru) 2005-01-20
HUP0302521A3 (en) 2007-03-28
BR0116762A (pt) 2004-08-10
ZA200305806B (en) 2005-01-26
HUP0302521A2 (hu) 2003-11-28
AR035411A1 (es) 2004-05-26
PL366301A1 (en) 2005-01-24
KR100794204B1 (ko) 2008-01-14
WO2002053159A1 (en) 2002-07-11
NZ527209A (en) 2005-09-30
EP1353671A1 (en) 2003-10-22
KR20070030331A (ko) 2007-03-15
AU2002231277B2 (en) 2006-11-30
EP1353671A4 (en) 2004-07-14
CA2433384A1 (en) 2002-07-11
RU2288716C2 (ru) 2006-12-10
CZ20032060A3 (cs) 2004-01-14
JP2004527472A (ja) 2004-09-09
KR20040007431A (ko) 2004-01-24
IL156664A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
DE60133189D1 (de) Aufblasvorrichtung
DK1307486T3 (da) Somatostatinanaloger
DE60108147D1 (de) Temperaturmessballon
NO20032101D0 (no) Apoliprotein analoger
DE60117334D1 (de) Gassack
EP1353683A4 (en) ANALOGS BY GHRELIN
DE60126694D1 (de) Beatmungsgerät
ATA16182001A (de) Einbau-wölb-verwind-stütze
DE60132401D1 (de) Tiefpassfilter
DE60107598D1 (de) Smart-skin strukturen
FI20000854A0 (fi) Adsorbenttikatalyytti
DE60206321D1 (de) Aufblasvorrichtung
DE60203590D1 (de) Aufblasvorrichtung
DE60226891D1 (de) Aufblasvorrichtung
DE60113294D1 (de) Aufblasvorrichtung
DE60212579D1 (de) Aufblasvorrichtung
DE60233830D1 (de) Haltekonsolen-Struktur
FI20010718A0 (fi) Ilmapallon kiinnitin
PL366301A1 (en) Neurotrophic tacrolimus analogs
DE60205683T2 (de) Aufblasvorrichtung
DE60143209D1 (de) Zweiport-demodulationseinrichtung
DE50105097D1 (de) Beatmungsgerät
DE50111882D1 (de) Verdeck
FR2813906B1 (fr) Plancher technique
DE50101803D1 (de) Prospektzug

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

CREP Change of representative

Representative=s name: ZACCO NORWAY AS POSTBOKS 2003 VIKA OSLO, 0125 NO

FC2A Withdrawal, rejection or dismissal of laid open patent application